The other GLP-1 peptide demonstrated to have clinical potential for type 2 diabetes was GLP-1 (7-36)
doi:10.1038/s41392-024-01951-9 Uusitupa M, Khan TA, Viguiliouk E, et al
Simply put, they make it much easier to eat less
This article explains the evidence around stopping GLP-1 therapy, what to expect when treatment ends, and how to discontinue safely under medical supervision in line with UK clinical guidance
Patients should seek prompt medical guidance for severe or persistent vomiting, signs of dehydration, severe abdominal pain, fainting, symptoms of low blood sugar, inability to keep fluids down, worsening constipation with pain or bloating, or any symptom that feels unsafe
Why is the market down now